Corcept Therapeutics Incorporated
$ 110.77
2.61%
07 Aug - close price
- Market Cap 11,974,059,000 USD
- Current Price $ 110.77
- High / Low $ 110.79 / 108.08
- Stock P/E 235.68
- Book Value 6.54
- EPS 0.47
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE 0.08 %
- 52 Week High 122.21
- 52 Week Low 28.66
About
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Analyst Target Price
$135.25
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-30 | 2026-02-24 | 2025-11-04 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-10-30 | 2024-07-29 | 2024-05-01 | 2024-02-15 | 2023-11-01 |
| Reported EPS | 0.36 | -0.3 | 0.2 | 0.16 | 0.29 | 0.17 | 0.26 | 0.41 | 0.32 | 0.25 | 0.28 | 0.28 |
| Estimated EPS | -0.04 | -0.14 | 0.254 | 0.14 | 0.19 | 0.14 | 0.4233 | 0.29 | 0.24 | 0.22 | 0.26 | 0.23 |
| Surprise | 0.4 | -0.16 | -0.054 | 0.02 | 0.1 | 0.03 | -0.1633 | 0.12 | 0.08 | 0.03 | 0.02 | 0.05 |
| Surprise Percentage | 1000% | -114.2857% | -21.2598% | 14.2857% | 52.6316% | 21.4286% | -38.5778% | 41.3793% | 33.3333% | 13.6364% | 7.6923% | 21.7391% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CORT
2026-08-08 08:10:48
Evanson Financial LLC recently acquired 12,478 shares of Corcept Therapeutics (NASDAQ:CORT) worth approximately $1.085 million. This purchase is part of broader institutional investor activity, with hedge funds owning 93.61% of the company's stock. Despite some analyst downgrades and insider selling, the company recently beat quarterly earnings and revenue expectations.
2026-08-08 07:10:49
Argus has raised its target price for Corcept Therapeutics Inc (CORT) to $100.00. The company is a commercial-stage pharmaceutical firm focused on developing medications for metabolic, oncologic, and neuropsychiatric disorders by modulating cortisol's effect. The current price of CORT stock is $110.77.
2026-08-08 01:39:41
Corcept Therapeutics (CORT) is gaining attention after its Q2 earnings report, which included increased full-year 2026 revenue guidance and a share buyback update. While the stock has shown significant positive momentum over the long term, Simply Wall St's analysis suggests it is currently 23% overvalued at $107.95 compared to a narrative fair value of $88.00. The company faces potential upside from new drug approvals and commercial scaling, but also risks from patent litigation and Korlym pricing pressure.
2026-08-07 13:10:49
William Guyer, Chief Development Officer at Corcept Therapeutics Inc., sold 3,700 shares of common stock for $418,561 on August 4, 2026, while also acquiring 3,700 shares by exercising stock options. This sale, conducted under a pre-arranged 10b5-1 plan, follows a significant 210% year-to-date surge in CORT shares. The company recently reported strong Q2 2026 financial results, including a 32% revenue increase and an upward revision of its full-year outlook.
2026-08-07 13:10:48
Corcept Therapeutics (CORT) has seen its stock gain significant momentum after lifting its full-year 2026 revenue guidance following its Q2 earnings report. Despite strong long-term performance and potential for future growth from new drug approvals, Simply Wall St's narrative suggests the stock is currently 23% overvalued at $107.95 compared to a fair value of $88.00, highlighting mixed sentiment due to ongoing patent litigation and pricing pressures on its existing product.
2026-08-07 00:09:31
William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold 3,700 shares of company stock for $418,561, while simultaneously exercising stock options to acquire the same number of shares. The sale followed a significant 210% surge in CORT shares year-to-date. This transaction was part of a pre-arranged trading plan, and Guyer continues to hold common stock and stock options in the company.
